Dr. Saad Usmani Discusses Effective Treatment for Relapsed/Refractory Multiple Myeloma

Janssen and Legend Biotech announced new efficacy and safety data for BCMA-directed CAR-T cell therapy cilta-cel in the treatment of relapsed or refractory multiple myeloma. The FDA recently granted priority review of cilta-cel’s biologic license application. The data were presented at this year’s ASCO 2021 Annual Meeting. DocWire News spoke with Saad Usmani, MD, one of the study’s investigators, to discuss these findings.